聯環藥業(600513.SH)獲1000萬元搬遷補償款
格隆匯1月7日丨聯環藥業(600513.SH)公佈,根據揚州市城市建設規劃需要,揚州市工業和信息化局(原揚州市經濟和信息化委員會)代表揚州市人民政府作為“退城進園”方案的牽頭部門,要求公司對揚州市文峯路21號地塊(權屬江蘇聯環藥業集團有限公司)進行搬遷。2016年5月3日公司與揚州市工業和信息化局(原揚州市經濟和信息化委員會)簽署了《搬遷補償協議》,公司及全資子公司揚州製藥有限公司將共計獲得人民幣1.89億元的搬遷補償費用。
公司於近日收到江蘇聯環藥業集團有限公司受託支付的搬遷補償款人民幣1000萬元。截至本公告日,公司及全資子公司累計收到搬遷補償款人民幣1.15億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.